Neoadjuvant nivolumab shows long-term benefit in patients with non–small cell lung cancer

Patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes, according to results published in Clinical Cancer Research.

https://www.lifetechnology.com/blogs/life-technology-medical-news/neoadjuvant-nivolumab-shows-long-term-benefit-in-patients-with-non-small-cell-lung-cancer

Buy SuperforceX™